Gruppo Italiano Trapianto di Midollo Osseo   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Italy (1987)

Organization Overview

First Clinical Trial
2000
NCT00435955
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Gruppo Italiano Trapianto di Midollo Osseo

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Febrile Neutropenia (Phase 2)

Graft vs Host Disease (Phase 1)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Lymphoma (Phase 3)

Lymphoma, Follicular (Phase 3)

Lymphoproliferative Disorders (Phase 3)

Neoplasms (Phase 2)

Primary Myelofibrosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 18